Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...
FierceBiotech4h
Frazier arms Callio with $187M series A to fly Hummingbird's HER2 dual payload ADC to clinic
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...
Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules
Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody ...
FierceBiotech23h
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart
Oqory’s planned reverse merger with fellow antibody-drug conjugate (ADC) company Vincerx Pharma has fallen apart at the last ...
FDA recognizes need for immunogenicity assays in therapeutics with carriers or conjugates
A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration ...
Contract Pharma2h
Callio Therapeutics Launches with $187M Series A
Callio Therapeutics, a biotechnology company, has launched with the closing of a $187.0 million Series A financing round.
SOTIO Biotech: SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer
SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO ...
‘Indian pharma’s capability, regulatory compliance help to tap global CDMO space’
Suven Pharmaceuticals Chairman discusses global outsourcing, growth strategies, and Phase 3 pipeline expansion in interview ...
Daily10h
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
PharmiWeb2h
Veranova Relocates Headquarters to Devens, MA
Veranova is pleased to announce the move of its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for manufacturing and development. Strategically ...
technologynetworks17h
Novel Reaction Enables the Precise Functionalization of Peptide Therapeutics
Researchers have applied a novel reaction to peptides produced using cell-free translation systems, providing a fast and ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously tr ...